LON:BMKBenchmark Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Benchmark Holdings PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 29 0.00 (0.00 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range 28.06Now: GBX 29▼ 29.1450-Day Range 26.50MA: GBX 31.56▼ 34.5052-Week Range 24Now: GBX 29▼ 56.90Volume33,267 shsAverage Volume102,168 shsMarket Capitalization£193.61 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsInsider TradesHeadlines Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge for the development of food and farming industries worldwide. The company operates through Animal Health, Benchmark Genetics, Advanced Animal Nutrition, and All Other segments. The Animal Health segment provides veterinary and environmental diagnostics services, and animal health products to aquaculture, as well as manufactures licensed veterinary vaccines and components. The Benchmark Genetics segment offers salmon breeding technologies and production facilities to the harnesses industry to provide a range of genetic merit ova. The Advanced Animal Nutrition segment manufactures and offers nutrition and health products to the aquaculture industry. The All Other segment provides sustainable food production and technical consultancy, and assurance services; and promotes sustainable food production and ethics through online news and technical publications for the international agriculture and food processing sectors, as well as through delivery of training courses to industries. Benchmark Holdings plc was founded in 2000 and is headquartered in Sheffield, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBenchmark has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 92, Benchmark has a potential upside of 217.2% from its current price of GBX 29.Amount of Analyst CoverageBenchmark has received no research coverage in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesBenchmark has received 235 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBenchmark has received 179 “underperform” votes. (Add your “underperform” vote.)Community SentimentBenchmark has received 56.76% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Benchmark and other stocks. Vote “Outperform” if you believe BMK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBenchmark does not currently pay a dividend.Dividend GrowthBenchmark does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Benchmark insiders have bought more of their company's stock than they have sold. Specifically, they have bought £5,070.76 in company stock and sold GBX 0 in company stock. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Benchmark is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Benchmark is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBenchmark has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.99 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:BMK Previous Symbol CUSIPN/A CIKN/A Webwww.benchmarkplc.com Phone+44-114-2409935Debt Debt-to-Equity Ratio38.68 Current Ratio2.40 Quick Ratio1.13Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£122.75 million Price / Sales1.58 Cash FlowGBX 3 per share Price / Cash Flow9.67 Book ValueGBX 49 per share Price / Book0.59Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares667,614,016Market Cap£193.61 million Next Earnings Date5/29/2020 (Estimated) OptionableNot Optionable LSE:BMK Rates by TradingView Receive BMK News and Ratings via Email Sign-up to receive the latest news and ratings for BMK and its competitors with MarketBeat's FREE daily newsletter. Benchmark (LON:BMK) Frequently Asked Questions How has Benchmark's stock been impacted by COVID-19 (Coronavirus)? Benchmark's stock was trading at GBX 34.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BMK shares have decreased by 15.3% and is now trading at GBX 29. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Benchmark? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Benchmark in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Benchmark. When is Benchmark's next earnings date? Benchmark is scheduled to release its next quarterly earnings announcement on Friday, May 29th 2020. View our earnings forecast for Benchmark. What price target have analysts set for BMK? 1 equities research analysts have issued 12-month target prices for Benchmark's shares. Their forecasts range from GBX 92 to GBX 92. On average, they expect Benchmark's share price to reach GBX 92 in the next year. This suggests a possible upside of 217.2% from the stock's current price. View analysts' price targets for Benchmark. Has Benchmark been receiving favorable news coverage? Press coverage about BMK stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Benchmark earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutBenchmark. Who are some of Benchmark's key competitors? Some companies that are related to Benchmark include HLS Therapeutics (HLS), OrganiGram (OGI), Next Science (NXS), Hexo (HEXO), ICC Labs (ICC), HEXO (HEXO), Amryt Pharma (AMYT), Green Organic Dutchman (TGOD), Probiotec (PBP), ESSA Pharma (EPI), CannTrust (TRST), Shield Therapeutics (STX), Supreme Cannabis (FIRE), Althea Group (AGH) and WeedMD (WMD). View all competitors. What other stocks do shareholders of Benchmark own? Based on aggregate information from My MarketBeat watchlists, some companies that other Benchmark investors own include Indivior (INDV), Allena Pharmaceuticals (ALNA), Redt Energy (RED), Ampliphi Biosciences (APHB), Clinigen Group (CLIN), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), American Campus Communities (ACC), AcelRx Pharmaceuticals (ACRX) and Aldeyra Therapeutics (ALDX). Who are Benchmark's key executives? Benchmark's management team includes the following people: Mr. Malcolm David Foster Pye, CEO & Exec. Director (Age 62)Mr. Mark James Plampin, CFO & Exec. Director (Age 51)Ms. Ruth Layton, Co-Founder & Head of Benchmark Sustainability ScienceDr. Alexander Josef Raeber, Chief Scientific Officer & Exec. Director (Age 58)Ms. Ivonne Cantu, Director of Investor Relations Director & Corp. Devel. What is Benchmark's stock symbol? Benchmark trades on the London Stock Exchange (LON) under the ticker symbol "BMK." How do I buy shares of Benchmark? Shares of BMK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Benchmark's stock price today? One share of BMK stock can currently be purchased for approximately GBX 29. How big of a company is Benchmark? Benchmark has a market capitalization of £193.61 million and generates £122.75 million in revenue each year. What is Benchmark's official website? The official website for Benchmark is www.benchmarkplc.com. How can I contact Benchmark? Benchmark's mailing address is Benchmark House, 8 Smithy Wood Drive, SHEFFIELD, S35 1QN, United Kingdom. The company can be reached via phone at +44-114-2409935. This page was last updated on 5/24/2020 by MarketBeat.com Staff
